The pathogenesis of human cytomegalovirus
- PMID: 25205255
- DOI: 10.1002/path.4437
The pathogenesis of human cytomegalovirus
Abstract
Human cytomegalovirus (HCMV) is a recognized cause of disease in the fetus, the allograft recipient and AIDS patients. More recently, it has been recognized as a pathogen for those admitted to intensive care units, for the elderly and for the general population. The epidemiology and molecular and cellular pathology of this virus are summarized to provide an overarching model of pathogenesis, able to account for these varying clinical presentations. In brief, HCMV has the potential to spread in the bloodstream to all organs, but only produces overt disease if the viral load increases to high levels. This is normally prevented by a robust immune response, so that the infected individual usually remains asymptomatic. However, this benefit comes at the cost of committing more and more immunological resources to controlling HCMV with time, so that the overall function of the immune system is impaired. Fortunately, recent progress in developing novel antiviral drugs and vaccines suggests the possibility that the diverse effects of HCMV may soon become controllable at the individual and population level, respectively.
Keywords: congenital; human cytomegalovirus; pre-emptive therapy; threshold; transplantation; viraemia.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Similar articles
-
Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation.PLoS One. 2019 Jan 25;14(1):e0210420. doi: 10.1371/journal.pone.0210420. eCollection 2019. PLoS One. 2019. PMID: 30682032 Free PMC article.
-
Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Rev Med Virol. 2016 May;26(3):161-82. doi: 10.1002/rmv.1873. Epub 2016 Mar 14. Rev Med Virol. 2016. PMID: 26990717 Review.
-
Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.J Antimicrob Chemother. 2003 Sep;52(3):324-30. doi: 10.1093/jac/dkg354. Epub 2003 Jul 29. J Antimicrob Chemother. 2003. PMID: 12888590 Review.
-
Drug targets in cytomegalovirus infection.Infect Disord Drug Targets. 2009 Apr;9(2):201-22. doi: 10.2174/187152609787847758. Infect Disord Drug Targets. 2009. PMID: 19275707 Review.
-
Pathogenesis of human cytomegalovirus in the immunocompromised host.Nat Rev Microbiol. 2021 Dec;19(12):759-773. doi: 10.1038/s41579-021-00582-z. Epub 2021 Jun 24. Nat Rev Microbiol. 2021. PMID: 34168328 Free PMC article. Review.
Cited by
-
Cytomegalovirus-Associated Gianotti-Crosti Syndrome in 28-Year-Old Immunocompetent Patient.Pathogens. 2022 Nov 12;11(11):1338. doi: 10.3390/pathogens11111338. Pathogens. 2022. PMID: 36422590 Free PMC article.
-
HCMV miRNA Targets Reveal Important Cellular Pathways for Viral Replication, Latency, and Reactivation.Noncoding RNA. 2018 Oct 22;4(4):29. doi: 10.3390/ncrna4040029. Noncoding RNA. 2018. PMID: 30360396 Free PMC article. Review.
-
Human monocyte-derived macrophages inhibit HCMV spread independent of classical antiviral cytokines.Virulence. 2018;9(1):1669-1684. doi: 10.1080/21505594.2018.1535785. Virulence. 2018. PMID: 30403913 Free PMC article.
-
Seasonal influence on TORCH infection and analysis of multi-positive samples with indirect immunofluorescence assay.J Clin Lab Anal. 2019 May;33(4):e22828. doi: 10.1002/jcla.22828. Epub 2019 Jan 21. J Clin Lab Anal. 2019. PMID: 30666721 Free PMC article.
-
The Complex Regulatory Role of Cytomegalovirus Nuclear Egress Protein pUL50 in the Production of Infectious Virus.Cells. 2021 Nov 11;10(11):3119. doi: 10.3390/cells10113119. Cells. 2021. PMID: 34831342 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical